BUDESONIDE INHALATION SUSPENSION suspension

Šalis: Jungtinės Valstijos

kalba: anglų

Šaltinis: NLM (National Library of Medicine)

Nusipirk tai dabar

Prekės savybės Prekės savybės (SPC)
16-12-2022

Veiklioji medžiaga:

BUDESONIDE (UNII: Q3OKS62Q6X) (BUDESONIDE - UNII:Q3OKS62Q6X)

Prieinama:

Ritedose Pharmaceuticals, LLC

Vartojimo būdas:

RESPIRATORY (INHALATION)

Recepto tipas:

PRESCRIPTION DRUG

Terapinės indikacijos:

1.1 Maintenance Treatment of Asthma Budesonide inhalation suspension is indicated for the maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age. Limitations of Use: - Budesonide inhalation suspension is NOT indicated for the relief of acute bronchospasm. The use of budesonide inhalation suspension is contraindicated in the following conditions: - Primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required. - Hypersensitivity to budesonide or any of the ingredients of budesonide inhalation suspension [see Warnings and Precautions (5.3), Description (11), Adverse Reactions (6.2)] . 8.1 Pregnancy Risk Summary There are no adequate well-controlled studies of budesonide inhalation suspension in pregnant women. However, there are published studies on the use of budesonide, the active ingredient in budesonide inhalation suspension, in pregnant women. In animal reproduction studies, budesonide, administered by the su

Produkto santrauka:

Budesonide inhalation suspension is supplied in sealed aluminum foil envelopes containing one single-dose ampule. There are 30 ampules in a carton. Each single-dose ampule contains 2 mL of white to off-white sterile liquid suspension. Budesonide inhalation suspension is available in single strength, containing 2 mL: Budesonide inhalation suspension should be stored upright at controlled room temperature 20 to 25°C (68 to 77°F) [see USP], and protected from light. When an envelope has been opened, the shelf life of the unused ampules is 2 weeks when protected. After opening the aluminum foil envelope, the unused ampules should be returned to the aluminum foil envelope to protect them from light. Any opened ampule must be used promptly. Gently shake the ampule using a circular motion before use. Keep out of reach of children. Do not freeze. FOR YOUR PROTECTION: Do not use if ampule appears damaged.

Autorizacija statusas:

Abbreviated New Drug Application

Prekės savybės

                                BUDESONIDE INHALATION SUSPENSION- BUDESONIDE INHALATION
SUSPENSION SUSPENSION
RITEDOSE PHARMACEUTICALS, LLC
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
BUDESONIDE INHALATION SUSPENSION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
BUDESONIDE INHALATION
SUSPENSION SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION
FOR BUDESONIDE
INHALATION SUSPENSION.
BUDESONIDE INHALATION SUSPENSION.
INITIAL U.S. APPROVAL: 2000
INDICATIONS AND USAGE
Budesonide inhalation suspension is an inhaled corticosteroid
indicated for: (1)
Maintenance treatment of asthma and as prophylactic therapy in
children 12 months to 8 years of age
(1)
Limitations of Use: (1)
Not indicated for the relief of acute bronchospasm (1) (1)
DOSAGE AND ADMINISTRATION
Recommended dosing based on previous therapy (2). Start with the
lowest recommended dose: (2)
Bronchodilators alone: 0.5 mg once daily or 0.25 mg twice daily
Inhaled corticosteroids: 0.5 mg once daily or 0.25 mg twice daily up
to 0.5 mg twice daily
Oral corticosteroids: 0.5 mg twice daily
In symptomatic children not responding to non-steroidal therapy, a
starting dose of
0.25 mg once daily may be considered
If once-daily treatment does not provide adequate control, the total
daily dose should be increased
and/or administered as a divided dose. Once asthma stability is
achieved, titrate the dose downwards
For inhalation use via compressed air driven jet nebulizers only (not
for use with ultrasonic devices). Not
for injection. (2.2)
DOSAGE FORMS AND STRENGTHS
Inhalation suspension: 0.5 mg/ 2mL (3) (3)
CONTRAINDICATIONS
Primary treatment of status asthmaticus or other acute episodes of
asthma where intensive measures
are required (4)
Hypersensitivity to any of the ingredients in budesonide inhalation
suspension (4)
WARNINGS AND PRECAUTIONS
Localized Infections: _Candida albicans_ infection of the mouth and
throat may occur. Monitor patients
periodically for signs of adverse effects on the oral cavity. Advise
patients to rinse the mouth following
inhalation (5.1)
Deteri
                                
                                Perskaitykite visą dokumentą
                                
                            

Ieškokite perspėjimų, susijusių su šiuo produktu